Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.
Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.
Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166559. doi: 10.1016/j.bbadis.2022.166559. Epub 2022 Sep 26.
Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the inflammatory state, the alteration of the adipokine profile, and cytokine production in the obese state of infected and not infected patients by SARS-CoV2 with the final aim to find possible influences of COVID-19 on CMD and CVD. The immunological-based discussion of the molecular processes could inspire the study of promising targets for managing CMD patients and its complications during COVID-19.
肥胖、2 型糖尿病(T2DM)、高血压(HTN)和心血管疾病(CVD)通常会聚集在一起形成“代谢心血管疾病”(CMD)。正如大多数受 SARS-CoV2 病毒影响的国家所报告的那样,CMD 患者中有近 50%的患者从 COVID-19 大流行一开始就增加了发病和死亡的风险。COVID-19 的一个病理生理学特征是免疫系统过度激活,伴有明显的 IL-6 反应,导致严重的全身性损伤,还涉及细胞因子,如 IL2、IL4、IL8、IL10 和干扰素-γ,被认为是 COVID-19 严重程度的强预测因子。因此,在这篇迷你综述中,我们试图描述感染和未感染 SARS-CoV2 的肥胖患者的炎症状态、脂联素谱的改变和细胞因子的产生,最终目的是寻找 COVID-19 对 CMD 和 CVD 的可能影响。基于免疫的分子过程的讨论可以为管理 CMD 患者及其在 COVID-19 期间的并发症提供有希望的目标的研究提供启示。